+22%

est. 2Y upside i

HealthcareSeries B

We make healthcare in emerging markets affordable and accessible

Rank

#1543

Sector

Digital Health

Est. Liquidity

~4Y

Data Quality

Data: Low

Assuming a $120M fair value (2.1x TTM revenue), the expected 2-year upside is ~22%, driven mostly by multiple expansion in a bull case.

Last updated: August 25, 2026

Bull (25%)+101%

Relarex ramps and an IPO window opens, pushing the multiple to 4.0x forward revenue ($241M exit). This requires re-accelerating growth from 3.5% and capturing public-market demand for emerging-market health tech.

Base (40%)+26%

Revenue grows modestly to ~$60M; the exit multiple settles at 2.5x, yielding a $151M enterprise value. With no near-term dilution, equity appreciates ~26% over two years.

Bear (35%)-37%

Growth stalls and the multiple compresses to 1.25x forward revenue ($75M exit), below the public comp range. The $48M preference stack still covers the exit, but common equity loses substantial value and liquidity risk remains.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

40%

$48M of preferred liquidation preference equals 40% of the assumed $120M entry valuation; common stock only captures value above $48M.

Dilution Risk

low

No imminent raise expected given the breakeven push and 2025 layoffs, but any future growth capital would dilute common stock.

Secondary Liquidity

none

No secondary market indicated; employee equity is likely illiquid until a liquidity event.

Questions to Ask at the Interview

Strategic questions based on Reliance Health's data — designed to show you've done your homework.

  • 1

    “How does Relarex change unit economics and what is the expected revenue mix in 24 months?”

  • 2

    “What are the latest gross margin and claims ratios across Nigeria and Egypt?”

  • 3

    “What is the fully-diluted share count, option pool percentage, and date of the last 409A valuation?”

Community

Valuation Sentiment

Our model estimates +22% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.